Drug Trial Radar · NCT00572156
rhGH and rhIGF-1 Combination Therapy in Children With Short Stature Associated With IGF-1 Deficiency
Last checked: Nov 20, 2026Latest source record: Mar 30, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
106
Actual
Start
Dec 2007
Primary completion
Apr 2010
Study completion Mar 2012
Sponsor
- Lead sponsor
- IpsenIndustry
- Sponsor type
- Industry
- First posted
- Dec 12, 2007
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 5 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
IGF-1 (insulin-like growth factor-1) is a hormone that is normally produced in the body in response to another hormone called growth hormone. Growth Hormone is produced by a small gland at the base of the brain (the pituitary). Together IGF-1 and GH are large contributors to growth during infancy, childhood, and adolescence. Children with IGF Deficiency are short and have an imbalance in the levels of growth hormone and IGF-1 that their body produces. Their growth hormone levels are normal or even high, but IGF-1 levels do not increase normally in response to growth hormone. As a result, they have a type of growth hormone insensitivity and an inability to grow normally. This study is a test to see whether daily dosing with a combination of rhIGF-1 and rhGH will help children with IGFD grow taller more quickly than children treated with rhGH alone. The study medications, rhIGF-1 and rhGH, are approved by the US Food and Drug Administration (FDA) for use in some growth disorders in children, but the combination of rhIGF-1 and rhGH in children with IGF-1 deficiency (IGFD) is investigational.
Conditions
- Insulin-like Growth Factor-1 Deficiency
Interventions
NutropinAq® (Somatropin [rDNA origin])Drug
rhGH (Somatropin) 45µg/kg once daily injection
Increlex® (Mecasermin [rDNA origin] injection) + NutropinAq® (Somatropin [rDNA origin])Drug
rhGH 45µg/kg and rhIGF-1 150µg/kg once daily injection
Increlex® (Mecasermin [rDNA origin] injection) + NutropinAq® (Somatropin [rDNA origin])Drug
rhGH (Somatropin) 45µg/kg and rhIGF-1 (Mecasermin) 50µg/kg once daily injections
Increlex® (Mecasermin [rDNA origin] injection) + NutropinAq® (Somatropin [rDNA origin])Drug
rhGH 45µg/kg and rhIGF-1 100µg/kg once daily injections
Primary outcomes
What the sponsor says the trial is designed to measure.
- Height VelocityTime frame: First year of treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Ipsen
Brisbane, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.